Abnova Promotion: 15% Off Biosimilars & ELISA Kits
-15% Biosimilar antibodies
-15% Antibody Drug (Free Drug) ELISA Kits
-15% Anti-Drug Antibody (ADA) ELISA Kits
Expires 30th June 2026. Not summable with other discounts.
15% Off Abnova Biosimilar Antibody Portfolio
Recombinant / Humanized Therapeutic Antibody Clones
Abnova’s Biosimilar Antibody portfolio includes over 140 biosimilar-related antibodies for biopharmaceutical research, biosimilar development, PK studies, immunogenicity testing, and therapeutic antibody analysis. The range features recombinant and humanized therapeutic antibody clones corresponding to major biologics , suitable for applications including ELISA, flow cytometry, western blot, immunofluorescence, immunohistochemistry, and functional assays.
Some representative of humanized therapeutic antibody clones include:
– Rituximab
– Bevacizumab
– Trastuzumab
– Adalimumab
– Cetuximab
– Nivolumab
– Pembrolizumab
Tocilizumab
15% Off Antibody Drug (Free Drug) ELISA Kits - Quantitative
Therapeutic Antibody Quantification
Abnova Antibody Drug ELISA Kits are designed to measure the concentration of free therapeutic antibodies in human samples, supporting studies such as pharmacokinetics (PK), therapeutic drug monitoring, and biosimilar evaluation.
The Abnova portfolio currently covers 35 widely used therapeutic antibodies, including several major biologics used in oncology, autoimmune diseases, and immunotherapy. These kits are valuable tools for pharmacokinetics, therapeutic drug monitoring, and biosimilar evaluation, helping researchers generate accurate and reproducible drug concentration data.
Some representative targets include:
– Adalimumab
– Infliximab
– Pembrolizumab
– Nivolumab
– Trastuzumab
– Bevacizumab
– Rituximab
– Ustekinumab
– Vedolizumab
– Atezolizumab
– Durvalumab
15% Off Anti-Drug Antibody (ADA) ELISA Kits
Immunogenicity Monitoring
Abnova ADA ELISA Kits support immunogenicity assessment by detecting anti-drug antibodies generated against therapeutic biologics. Available in qualitative, quantitative, and semi-quantitative formats, these kits help streamline immunogenicity studies in both preclinical and clinical research. Abnova’s ADA product line includes 55 kits, covering many major biologics.
Examples include ADA detection kits for:
– Anti-Adalimumab
– Anti-Infliximab
– Anti-Pembrolizumab
– Anti-Nivolumab
– Anti-Trastuzumab
– Anti-Bevacizumab
– Anti-Rituximab
– Anti-Tocilizumab